New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.74 0.01 +0.13%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

Where the cash went Twelve months to Sep 30, 2026

Free cash flow was −$243.2M: capital expenditures were more than operating cash flow. Cash fell by $56.3M. What is a cash flow statement?

Free cash flow
−$243.2M
Returned to shareholders
$6.1M
Debt, net
$36.4M borrowed
Change in cash
−$56.3M over the period
Where the cash went, in millions of dollars
Operating cash flow−238.9
Capital expenditures−4.3
Free cash flow−243.2
From investments, net+100.5
Buybacks, net−6.1
Debt raised, net+36.4
Other+56.2
Change in cash−56.3
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow−$245M−$92M−$37M−$239M
Capex−$5.6M−$5.2M−$5.3M−$4.3M
Free cash flow−$250M−$97M−$42M−$243M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
(76.73) (247.73) (87.83) 440.30

+8 more TTM periods

Operating Cash Flow
(238.95) (36.90) (91.56) (244.63)
Investing cash flow
154.80 (109.51) (33.31) (78.27)
Financing cash flow
30.27 74.71 72.47 27.74
Ending Cash
199.75 183.11 210.50 256.05

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026